Correlation Between Visa and Halozyme Therapeutics
Can any of the company-specific risk be diversified away by investing in both Visa and Halozyme Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Visa and Halozyme Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Visa Class A and Halozyme Therapeutics, you can compare the effects of market volatilities on Visa and Halozyme Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Visa with a short position of Halozyme Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Visa and Halozyme Therapeutics.
Diversification Opportunities for Visa and Halozyme Therapeutics
-0.38 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Visa and Halozyme is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Visa Class A and Halozyme Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Halozyme Therapeutics and Visa is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Visa Class A are associated (or correlated) with Halozyme Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Halozyme Therapeutics has no effect on the direction of Visa i.e., Visa and Halozyme Therapeutics go up and down completely randomly.
Pair Corralation between Visa and Halozyme Therapeutics
Taking into account the 90-day investment horizon Visa Class A is expected to generate 0.38 times more return on investment than Halozyme Therapeutics. However, Visa Class A is 2.63 times less risky than Halozyme Therapeutics. It trades about 0.07 of its potential returns per unit of risk. Halozyme Therapeutics is currently generating about 0.01 per unit of risk. If you would invest 22,590 in Visa Class A on August 27, 2024 and sell it today you would earn a total of 8,402 from holding Visa Class A or generate 37.19% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Visa Class A vs. Halozyme Therapeutics
Performance |
| Timeline |
| Visa Class A |
| Halozyme Therapeutics |
Visa and Halozyme Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Visa and Halozyme Therapeutics
The main advantage of trading using opposite Visa and Halozyme Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Visa position performs unexpectedly, Halozyme Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will offset losses from the drop in Halozyme Therapeutics' long position.| Visa vs. American Express | Visa vs. Morningstar Unconstrained Allocation | Visa vs. Sitka Gold Corp | Visa vs. MSCI ACWI exAUCONSUMER |
| Halozyme Therapeutics vs. Agios Pharm | Halozyme Therapeutics vs. Insmed Inc | Halozyme Therapeutics vs. Ultragenyx | Halozyme Therapeutics vs. Biomarin Pharmaceutical |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |